A clinical study of drug Apamarga for the treatment in patients of Piles

A pharmaco-clinical study of Apamarga (Achyranthes aspera Linn.) in the management of Sravi Arsha W.S.R. to Haemorrhoids - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/08/056827

Enrollment

Registered

2023-08-23

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K928- Other specified diseases of the digestive system

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1 Age group 18-60 years 2 Sex both male and female 3 1st and 2nd grade of haemorrhoids

Exclusion criteria

Exclusion criteria: 1 Pregnancy lactating mother 2 3rd and 4th grade of haemorrhoids 3 Patients with malignancy 4 Ulcerative colitis crohns disease

Design outcomes

Primary

Measure	Time frame
Subjective parameter Grading will be done with signs symptoms of Sravi Arsha Hb TLC DLC ESR LFT RFT Digital Examination Proctoscopy levels for Haemorrhoids.Timepoint: After one month intervention of Apamarga Ghana capsule orally 15 days after stopping of medicine	—

Secondary

Measure	Time frame
Subjective Parameter- Grading will be done with signs & symptoms of Sravi Arsha respectively. HB,TLC,DLC,ESR,Digital Examination,LFT RFT Proctoscopy levels for HaemorrhoidsTimepoint: After one month intervention of Apamarga Ghana capsule orally 15 days after stopping of medicine	—

Countries

India

Contacts

Public ContactDr Minakshi Kaundal

Post graduate training and research institute Government Ayurvedic College Patiala

minakshikaundal890@gmail.com8894688820

Outcome results